Citations 3
Clinical Heterogeneity of Neuronal Ceroid Lipofuscinosis Type 13
Ghayal, Nikhil B , Roemer, Shanu F. , Tipton, Philip W. , Jiang, Peizhou , Selner, Elizabeth M., Peck, Dawn , Murakami, Aya , Oglesbee, Devin , Graff‐Radford, Neill R. , Dickson, Dennis W. , Peck, Dawn S, Dickson, Dennis W , Graff-Radford, Neill R , Oglesbee, Devin , Tipton, Philip W , Ghayal, Nikhil B
Neurology Genetics | December 23, 2024 | Volume: 11 | Issue: 1 | Pages: No page available
Clinical, biochemical and genetic characteristics of MOGS-CDG: a rare congenital disorder of glycosylation
Shimada, Shino , Ng, Bobby G. , White, Amy , Nickander, Kim K., Turgeon, Coleman , Liedtke, Kristen, Lam, Christina , Font–Montgomery, Esperanza , Peck, Dawn , Uhles, Crescenda L , Haynes, Devon , Wheeler, Patricia G. , Bamshad, Michael J. , Nickerson, Deborah A. , Cushing, Tom, Gates, Ryan , Gomez‐Ospina, Natalia , Scalco, Fernanda B. , Martinez, Noelia Nunez, Sachdev, Rani , Malone, Stephen , Harris, Rebekah V. , Scheffer, Ingrid E. , Rosenzweig, Sergio D. , Adams, David R. , Gahl, William A. , Malicdan, May Christine V. , Raymond, Kimiyo , Wolfe, Lynne A. , Jarvik, Gail P. , White, Amy L , Liedtke, Kristen L, Peck, Dawn S, Harris, Rebekah V , Scheffer, Ingrid E , Malicdan, May Christine V , Raymond, Kimiyo M, Jarvik, Gail P , Ng, Bobby G , Lourenco, Charles , He, Miao , Umaña, Luis Alfredo , Byers, Heather M. , Smith, Lacey A. , Poduri, Annapurna , Freeze, Hudson H.
Journal of Medical Genetics | July 5, 2022 | Volume: 59 | Issue: 11 | Pages: 1104-1115
Purpose To summarise the clinical, molecular and biochemical phenotype of mannosyl-oligosaccharide glucosidase-related congenital disorders of glycosylation (MOGS-CDG), which presents with variable clinical manifestations, and to analyse which clinical biochemical assay consistently supports diagnosis in individuals with bi-allelic variants in MOGS. Methods Phenotypic characterisation was performed through an international and multicentre collaboration. Genetic testing was done by exome sequencing and targeted arrays. Biochemical assays on serum and urine were performed to delineate the biochemical signature of MOGS-CDG. Results Clinical phenotyping revealed heterogeneity in MOGS-CDG, including neurological, immunological and skeletal phenotypes. Bi-allelic variants in MOGS were identified in 12 individuals from 11 families. The severity in each organ system was variable, without definite genotype correlation. Urine oligosaccharide analysis was consistently abnormal for all affected probands, whereas other biochemical analyses such as serum transferrin analysis was not consistently abnormal. Conclusion The clinical phenotype of MOGS-CDG includes multisystemic involvement with variable severity. Molecular analysis, combined with biochemical testing, is important for diagnosis. In MOGS-CDG, urine oligosaccharide analysis via matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry can be used as a reliable biochemical test for screening and confirmation of disease.
Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I
Peck, Dawn , Lacey, Jean M., White, Amy , Pino, Gisele , Studinski, April, Fisher, Rachel , Ahmad, Ayesha , Viall, Sarah , Shallow, Natalie, Siemon, Amy, Hamm, J. Austin, Murray, Brianna K., Jones, Kelly L. , Gavrilov, Dimitar , Oglesbee, Devin , Raymond, Kimiyo , Matern, Dietrich , Rinaldo, Piero, Tortorelli, Silvia , Price, Theodore J. , Peck, Dawn S, White, Amy L , Studinski, April L, Jones, Kelly L , Oglesbee, Devin , Price, Theodore J , Spencer, Linda J. , Murray, Brianna K.
International Journal of Neonatal Screening | February 7, 2020 | Volume: 6 | Issue: 1 | Pages: 10
Enzyme-based newborn screening for Mucopolysaccharidosis type I (MPS I) has a high false-positive rate due to the prevalence of pseudodeficiency alleles, often resulting in unnecessary and costly follow up. The glycosaminoglycans (GAGs), dermatan sulfate (DS) and heparan sulfate (HS) are both substrates for α-l-iduronidase (IDUA). These GAGs are elevated in patients with MPS I and have been shown to be promising biomarkers for both primary and second-tier testing. Since February 2016, we have measured DS and HS in 1213 specimens submitted on infants at risk for MPS I based on newborn screening. Molecular correlation was available for 157 of the tested cases. Samples from infants with MPS I confirmed by IDUA molecular analysis all had significantly elevated levels of DS and HS compared to those with confirmed pseudodeficiency and/or heterozygosity. Analysis of our testing population and correlation with molecular results identified few discrepant outcomes and uncovered no evidence of false-negative cases. We have demonstrated that blood spot GAGs analysis accurately discriminates between patients with confirmed MPS I and false-positive cases due to pseudodeficiency or heterozygosity and increases the specificity of newborn screening for MPS I.